The present invention relates to carbazole derivatives, especially for use in electronic devices. The invention further relates to a process for preparing the compounds of the invention and to electronic devices comprising these.

The present disclosure relates to an organic electroluminescent compound and an organic electroluminescent device comprising the same. By comprising the organic electroluminescent compound of the present disclosure, an organic electroluminescent device having improved driving voltage, luminous efficiency, and/or lifespan characteristics can be provided.

The present invention relates to a cyanoaryl substituted compound of formula (I), (I) wherein m is 0-4; R.sup.2, R.sup.3, R.sup.4 and R.sup.5 are selected from hydrogen, chlorine, bromine and C.sub.6-C.sub.24-aryl, which carries one to three cyano; each R.sup.1 independently from each other is selected from bromine, chlorine, cyano, NRaRb, C.sub.1-C.sub.24-alkyl, C.sub.1-C.sub.24-haloalkyl, C1-C24-alkoxy, C.sub.1-C.sub.24-haloalkoxy, C.sub.3-C.sub.24-cycloalkyl, heterocycloalkyl, heteroaryl, C.sub.6-C.sub.24-aryl, C.sub.6-C.sub.24-aryloxy, C.sub.6-C.sub.24-aryl-C.sub.1-C.sub.10-alkylene, etc., with the proviso that at least one of the radicals R.sup.1, R.sup.2, R.sup.3, R.sup.4 and R.sup.5 is C.sub.6-C.sub.24-aryl, which carries one to three cyano; X is O, S, SO or SO.sub.2; A is a diradical of the formulae (A.1), (A.2), (A.3), or (A.4) wherein *, R.sup.6, (R.sup.7)n, (R.sup.8)o and (R.sup.9)p are as defined in the claims and in the description. The invention also relates to the use of said compound(s) in color converters, to said color converters and their use, to lighting devices, to a backlight unit for liquid crystal displays; a liquid crystal display device and a self-emissive display device comprising at least one compound (I).

##STR00001##

Provided herein are ergoline compounds and pharmaceutical compositions thereof. In some embodiments, provided herein are methods of treatment, prevention, or amelioration of a variety of medical disorders such as, for example, migraine using the compounds and pharmaceutical compositions disclosed herein. In still other embodiments, provided herein are methods of agonizing receptors such as, for example, the 5-HT.sub.1A, 5-HT.sub.1B and 5-HT.sub.1D receptors without agonizing the 5-HT.sub.2B receptor using the compounds and pharmaceutical compositions disclosed herein. In still other embodiments, provided herein are methods of antagonizing the 5-HT.sub.2B adrenergic alpha.sub.2A and/or the alpha.sub.2B receptors using the compounds and pharmaceutical compositions disclosed herein. In still other embodiments, provided herein are methods of antagonizing the D2 and D3 receptor using the compounds and pharmaceutical compositions disclosed herein.

Provided herein are ergoline compounds and pharmaceutical compositions thereof. In some embodiments, provided herein are methods of treatment, prevention, or amelioration of a variety of medical disorders such as, for example, migraine using the compounds and pharmaceutical compositions disclosed herein. In still other embodiments, provided herein are methods of agonizing receptors such as, for example, the 5-HT.sub.1A, 5-HT.sub.1B and 5-HT.sub.1D receptors without agonizing the 5-HT.sub.2B receptor using the compounds and pharmaceutical compositions disclosed herein. In still other embodiments, provided herein are methods of antagonizing the 5-HT.sub.2B adrenergic alpha.sub.2A and/or the alpha.sub.2B receptors using the compounds and pharmaceutical compositions disclosed herein. In still other embodiments, provided herein are methods of antagonizing the D2 and D3 receptor using the compounds and pharmaceutical compositions disclosed herein.

The present disclosure relates to an organic electroluminescent compound and an organic electroluminescent device comprising the same. The organic electroluminescent device having a low driving voltage and/or a high luminous efficiency and/or a long lifespan can be provided, by comprising an organic electroluminescent compound according to the present disclosure.

Provided herein are broad-spectrum G-Protein coupled receptor (GPCR) binding agents, detectable/isolatable compounds comprising such binding agents (e.g., broad-spectrum GPCR binding agents linked to a functional element and/or solid surface), and methods of use thereof for the detection/isolation of GPCRs.

Provided herein are broad-spectrum G-Protein coupled receptor (GPCR) binding agents, detectable/isolatable compounds comprising such binding agents (e.g., broad-spectrum GPCR binding agents linked to a functional element and/or solid surface), and methods of use thereof for the detection/isolation of GPCRs.

An organic electroluminescence device according to an embodiment of the present disclosure includes a first electrode, a hole transport region, an emission layer, an electron transport region, and a second electrode, in which the emission layer includes a polycyclic compound represented by Formula 1, thereby achieving improved emission efficiency:

##STR00001##

An organic electroluminescence device according to an embodiment of the present disclosure includes a first electrode, a hole transport region, an emission layer, an electron transport region, and a second electrode, in which the emission layer includes a polycyclic compound represented by Formula 1, thereby achieving improved emission efficiency:

##STR00001##